# Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid Leukemia

> **NCT05330364** · PHASE2 · UNKNOWN · sponsor: **Ge Zheng** · enrollment: 31 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Chidamide
- **DRUG:** Cladribine

## Key facts

- **NCT ID:** NCT05330364
- **Lead sponsor:** Ge Zheng
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-01
- **Primary completion:** 2023-06
- **Final completion:** 2023-06
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2022-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05330364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05330364, "Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05330364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*